Literature DB >> 3139779

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

B Vogelman1, S Gudmundsson, J Leggett, J Turnidge, S Ebert, W A Craig.   

Abstract

Current antimicrobial dosing regimens are designed to maintain active drug levels for most of the dosing interval and are based on 40-y-old observations. With use of numerous multiple-dosing regimens in an animal model, this study is the first to successfully minimize the interdependence between pharmacokinetic parameters and thereby determine, by stepwise multivariate regression analysis, that the time that serum levels exceeded the minimum inhibitory concentration (MIC) was the most significant parameter determining efficacy for beta-lactams and erythromycin against various pathogens, whereas the log area under the curve was the major parameter for aminoglycosides. Optimal dosing intervals were no greater than the time that serum levels exceeded the MIC plus the duration of the postantibiotic effect. Careful application of these concepts should allow other investigators to use more optimally dosed regimens than those previously used in preclinical trials and to design studies to improve on current dosing regimens for humans.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3139779     DOI: 10.1093/infdis/158.4.831

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  224 in total

1.  In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.

Authors:  D Szabó; A Máthé; Z Filetóth; P Anderlik; L Rókusz; F Rozgonyi
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 2.  Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  R C Li; M Zhu; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

3.  Use of Modeling Techniques to Aid in Antibiotic Selection.

Authors:  Alexander A. Firsov; Stephen H. Zinner
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

4.  Assumed versus approved breakpoints.

Authors:  D A Preston; M R Turnak
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

5.  Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.

Authors:  B J Angus; M D Smith; Y Suputtamongkol; H Mattie; A L Walsh; V Wuthiekanun; W Chaowagul; N J White
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 6.  In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.

Authors:  David Andes
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 7.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

8.  Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids.

Authors:  F Shojaee Aliabadi; M F Landoni; P Lees
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 9.  Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis.

Authors:  A C Cremieux; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 10.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.